12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ladostigil: Completed Phase II enrollment

Avraham completed enrollment of about 200 patients in a double-blind, placebo-controlled, European Phase II trial evaluating 80 mg oral ladostigil twice daily for 26 weeks in patients with mild to moderate AD. Avraham has...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >